Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
Vamorolone is Currently Under Review with the FDA (PDUFA Date of October 26, 2023) for the Treatment of Duchenne Muscular Dystrophy, a Rare Neuromuscular Disease
Vamorolone is Currently Under Review with the FDA for the Treatment of Duchenne Muscular Dystrophy, a Rare Neuromuscular Disease FDA has Granted Fast Track and Orphan Drug Designation for Vamorolone. | June 20, 2023